Adicet Bio Reports $20.2 Million Net Loss in Q1 2026, Reduces Operating Expenses

Adicet Bio, Inc. reported a net loss of $20.2 million for the first quarter of 2026, a decrease from the $28.2 million loss recorded in the same period of 2025. The company's total operating expenses for the quarter were $21.6 million, down 28% from $29.9 million year-over-year. This reduction was primarily driven by a 23% decrease in research and development expenses, which fell to $17.5 million from $22.8 million, and a 42% decline in general and administrative expenses, which decreased to $4.1 million from $7.1 million. The decrease in expenses reflects the company's ongoing efforts to streamline operations and reduce costs.

Adicet's cash, cash equivalents, and short-term investments totaled $137.6 million as of March 31, 2026, compared to $160.9 million at the end of 2025. The company has not generated any revenue from product sales, as none of its product candidates have received regulatory approval. The only revenue to date has come from a collaboration agreement with Regeneron Pharmaceuticals, which has not resulted in any significant product revenue. The company anticipates continued operating losses as it advances its clinical programs.

In terms of operational developments, Adicet is progressing with its lead product candidate, prula-cel, which is being evaluated in a Phase 1 clinical trial for various autoimmune diseases. The U.S. Food and Drug Administration (FDA) has cleared the IND application for prula-cel in lupus nephritis and systemic lupus erythematosus, among other indications. The company plans to provide updates on clinical trials in mid-2026, including data from at least 20 patients with a minimum of six months of follow-up. Additionally, Adicet is advancing ADI-212, a next-generation candidate targeting prostate-specific membrane antigen, with plans to submit a regulatory filing in the third quarter of 2026.

Adicet's workforce has been reduced as part of a strategic pipeline prioritization, which is expected to yield operational efficiencies. The company continues to rely on third-party suppliers for manufacturing, which poses risks related to production timelines and costs. The company has also indicated that it will need substantial additional financing to support the development of its product candidates and operational plans. The outlook remains cautious, with management acknowledging the potential for significant challenges in obtaining regulatory approvals and commercializing its therapies.